Abbott Laboratories Management
Management criteria checks 3/4
Abbott Laboratories' CEO is Robert Ford, appointed in Oct 2018, has a tenure of 5.5 years. total yearly compensation is $23.27M, comprised of 6.4% salary and 93.6% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $44.24M. The average tenure of the management team and the board of directors is 5 years and 5.2 years respectively.
Key information
Robert Ford
Chief executive officer
US$23.3m
Total compensation
| CEO salary percentage | 6.4% |
| CEO tenure | 5.5yrs |
| CEO ownership | 0.02% |
| Management average tenure | 5yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15
Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King
Dec 28Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Dec 27Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio
Dec 03Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?
Nov 29Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market
Nov 26Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?
Nov 01Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up
Oct 24Abbott: A Diversified Health Care Company With Strong Underlying Growth
Oct 20Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience
Sep 29Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price
Sep 26Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income
Sep 17We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt
Aug 13Abbott: This Dividend King Is Ready For Takeoff
Jul 31Abbott Laboratories Q2 2023 Earnings Preview: Expect Incremental Improvement
Jul 17The Big Trends: New Frontiers in Healthcare
Jul 13
Abbott Laboratories (NYSE:ABT) Is Experiencing Growth In Returns On Capital
Jul 12Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Jun 25Abbott Laboratories: Offers Promising Buying Opportunity (Technical Analysis)
Jun 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$23m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$22m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$8b |
| Jun 30 2022 | n/a | n/a | US$9b |
| Mar 31 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$25m | US$1m | US$7b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$6b |
| Dec 31 2020 | US$20m | US$1m | US$4b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$12m | US$1m | US$4b |
| Sep 30 2019 | n/a | n/a | US$3b |
| Jun 30 2019 | n/a | n/a | US$3b |
| Mar 31 2019 | n/a | n/a | US$3b |
| Dec 31 2018 | US$8m | US$784k | US$2b |
| Sep 30 2018 | n/a | n/a | US$802m |
| Jun 30 2018 | n/a | n/a | US$812m |
| Mar 31 2018 | n/a | n/a | US$365m |
| Dec 31 2017 | US$5m | US$675k | US$344m |
Compensation vs Market: Robert's total compensation ($USD23.27M) is above average for companies of similar size in the US market ($USD13.53M).
Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.
CEO
Robert Ford (49 yo)
5.5yrs
Tenure
US$23,268,171
Compensation
Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 5.5yrs | US$23.27m | 0.024% $ 44.2m | |
| CFO & Senior VP of Finance | less than a year | US$3.32m | 0.0023% $ 4.2m | |
| Executive VP | 11.3yrs | US$7.42m | 0.011% $ 19.6m | |
| Executive Vice President of Finance | less than a year | US$8.99m | 0.016% $ 28.7m | |
| Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | 9.6yrs | US$5.93m | 0.0072% $ 13.3m | |
| Executive VP & Group President of Medical Devices | 5.3yrs | US$5.50m | 0.0049% $ 8.9m | |
| Senior VP of Business & Technology Services and Chief Information Officer | less than a year | no data | no data | |
| VP and Chief Ethics & Compliance Officer | no data | no data | no data | |
| Vice President of Public Affairs & Corporate Marketing | no data | no data | no data | |
| Senior Vice President of Commercial Operations | 1.3yrs | no data | no data | |
| Executive Vice President of Human Resources | 4.7yrs | no data | 0.0059% $ 10.9m | |
| Executive Vice President of Diabetes Care | 8.8yrs | no data | 0.0042% $ 7.6m |
5.0yrs
Average Tenure
53yo
Average Age
Experienced Management: ABT's management team is considered experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 4.4yrs | US$23.27m | 0.024% $ 44.2m | |
| Independent Director | 7.2yrs | US$349.29k | 0.39% $ 711.1m | |
| Independent Director | 7.3yrs | US$316.95k | 0.00020% $ 367.8k | |
| Lead Independent Director | 12.3yrs | US$335.95k | 0.00027% $ 496.5k | |
| Independent Director | 3yrs | US$337.96k | 0% $ 0 | |
| Independent Director | 15.5yrs | US$441.44k | 0% $ 0 | |
| Independent Director | less than a year | US$283.96k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$316.95k | 0.00018% $ 331.0k | |
| Independent Director | 12.3yrs | US$340.70k | 0.00015% $ 275.8k | |
| Independent Director | 1.6yrs | US$31.50k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$331.19k | 0% $ 0 | |
| Independent Director | 2.7yrs | US$356.96k | 0% $ 0 |
5.2yrs
Average Tenure
61yo
Average Age
Experienced Board: ABT's board of directors are considered experienced (5.2 years average tenure).